title: Evolution of genetic instability in heterogeneous tumors.
abstract: Genetic instability is an important characteristic of cancer. While most cancers develop genetic instability at some stage of their progression, sometimes a temporary rise of instability is followed by the return to a relatively stable genome. Neither the reasons for these dynamics, nor, more generally, the role of instability in tumor progression, are well understood. In this paper we develop a class of mathematical models to study the evolutionary competition dynamics among different sub-populations in a heterogeneous tumor. We observe that despite the complexity of this multi-component and multi-process system, there is only a small number of scenarios expected in the context of the evolution of instability. If the penalty incurred by unstable cells (the decrease in the growth due to deleterious mutations) is high compared with the gain (the production rate of advantageous mutations), then instability does not evolve. In the opposite case, instability evolves and comes to dominate the system. In the intermediate parameter regime, instability is generated but later gives way to stable clones. Moreover, the model also informs us of the patterns of instability for cancer lineages corresponding to different stages of progression. It is predicted that mutations causing instability are merely "passengers" in tumors that have undergone only a small number of malignant mutations. Further down the path of carcinogenesis, however, unstable cells are more likely to give rise to the winning clonal wave that takes over the tumor and carries the evolution forward, thus conferring a causal role of the instability in such cases. Further, each individual clonal wave (i.e. cells harboring a fixed number of malignant driver mutations) experiences its own evolutionary history. It can fall under one of three types of temporal behavior: stable throughout, unstable to stable, or unstable throughout. Which scenario is realized depends on the subtle (but predictable) interplay among mutation rates and the death toll associated with the instability. The modeling approach provided here sheds light onto important aspects of the evolutionary dynamics of instability, which may be relevant to treatment scenarios that target instability or damage repair.
authors.affiliation: Department of Mathematics, University of California Irvine, Irvine, CA 92697, United States.
authors.forename: Ani D
authors.initials: AD
authors.lastname: Asatryan
authors.affiliation: Department of Mathematics, University of California Irvine, Irvine, CA 92697, United States; Department of Ecology and Evolutionary Biology, University of California Irvine, Irvine, CA 92697, United States. Electronic address: komarova@uci.edu.
authors.forename: Natalia L
authors.initials: NL
authors.lastname: Komarova
mesh_terms: D000818:Animals; D042822:Genomic Instability; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology
keywords: Chromosomal instability; Driver mutation; Microsatellite instability; Passenger mutation
references.citation: Nat Genet. 2000 Sep;26(1):114-7
references.pmid: 10973262
references.citation: Mol Cell. 1998 Aug;2(2):259-65
references.pmid: 9734364
references.citation: Nature. 2012 Jan 18;481(7381):287-94
references.pmid: 22258607
references.citation: Nat Rev Cancer. 2011 Jun;11(6):450-7
references.pmid: 21593786
references.citation: Oncogene. 2004 Apr 29;23(20):3561-71
references.pmid: 15077181
references.citation: Evol Appl. 2013 Jan;6(1):20-33
references.pmid: 23396531
references.citation: Cancer Res. 2001 Apr 15;61(8):3230-9
references.pmid: 11309271
references.citation: Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10002-7
references.pmid: 10944189
references.citation: Cancer Res. 2012 Oct 1;72(19):4875-82
references.pmid: 23002210
references.citation: Proc Natl Acad Sci U S A. 2004 May 4;101(18):7017-21
references.pmid: 15105448
references.citation: Nat Cell Biol. 2009 Jan;11(1):27-35
references.pmid: 19060894
references.citation: Nat Genet. 2001 Jun;28(2):155-9
references.pmid: 11381263
references.citation: Oncogene. 1997 Dec 18;15(25):3025-35
references.pmid: 9444951
references.citation: J Theor Biol. 2008 Sep 21;254(2):229-38
references.pmid: 18640693
references.citation: Trends Cell Biol. 2001 Jan;11(1):18-21
references.pmid: 11146294
references.citation: Cancer Res. 2002 Dec 1;62(23):7075-82
references.pmid: 12460929
references.citation: Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6468-73
references.pmid: 21451132
references.citation: Genetics. 2000 Sep;156(1):297-304
references.pmid: 10978293
references.citation: J Mol Cell Biol. 2011 Feb;3(1):1-3
references.pmid: 21278445
references.citation: Nat Rev Cancer. 2008 Mar;8(3):193-204
references.pmid: 18256616
references.citation: Front Oncol. 2013 Jun 07;3:148
references.pmid: 23760367
references.citation: Nat Rev Cancer. 2012 Sep;12(9):587-98
references.pmid: 22918414
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14800-3
references.pmid: 8962135
references.citation: J Mol Med (Berl). 2007 Feb;85(2):139-48
references.pmid: 17180667
references.citation: PLoS Comput Biol. 2007 Nov;3(11):e225
references.pmid: 17997597
references.citation: Trends Cell Biol. 1999 Dec;9(12):M57-60
references.pmid: 10611684
references.citation: J R Soc Interface. 2008 Jan 6;5(18):105-21
references.pmid: 17580291
references.citation: Nat Rev Cancer. 2008 Mar;8(3):180-92
references.pmid: 18273037
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Science. 2008 Mar 7;319(5868):1352-5
references.pmid: 18323444
references.citation: Mol Cell. 2005 Mar 18;17(6):793-803
references.pmid: 15780936
references.citation: Nature. 2013 Sep 19;501(7467):338-45
references.pmid: 24048066
references.citation: Nat Genet. 2004 Sep;36(9):984-8
references.pmid: 15300252
references.citation: Annu Rev Pathol. 2011;6:479-507
references.pmid: 21090969
references.citation: Annu Rev Pharmacol Toxicol. 2004;44:239-67
references.pmid: 14744246
references.citation: Mutat Res. 2000 Apr;462(2-3):149-58
references.pmid: 10767626
references.citation: Cancer Cell. 2008 Dec 9;14 (6):435-46
references.pmid: 19061835
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31
references.pmid: 12446840
references.citation: Bull Math Biol. 2014 Nov;76(11):2737-84
references.pmid: 25338553
references.citation: Curr Opin Genet Dev. 2000 Feb;10(1):39-46
references.pmid: 10679392
references.citation: Nature. 1997 Apr 10;386(6625):623-7
references.pmid: 9121588
references.citation: Risk Anal. 1988 Sep;8(3):383-92
references.pmid: 3201016
references.citation: Nature. 1997 Apr 24;386(6627):761, 763
references.pmid: 9126728
references.citation: Exp Cell Res. 2000 Aug 1;258(2):310-21
references.pmid: 10896782
references.citation: Nat Rev Cancer. 2012 Dec;12(12):801-17
references.pmid: 23175119
references.citation: Endocr Relat Cancer. 2014 Oct;21(5):R395-407
references.pmid: 25096064
references.citation: EMBO Rep. 2001 Sep;2(9):800-7
references.pmid: 11520856
references.citation: Biol Direct. 2010 Apr 20;5:19; discussion 19
references.pmid: 20406436
references.citation: Cancer Biol Ther. 2002 Nov-Dec;1(6):685-92
references.pmid: 12642695
references.citation: Cancer Res. 1988 Nov 1;48(21):5911-6
references.pmid: 3048652
references.citation: Cancer Res. 2010 Sep 1;70(17):6797-803
references.pmid: 20656803
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16284-9
references.pmid: 18936480
references.citation: Nat Rev Cancer. 2011 Apr;11(4):239-53
references.pmid: 21430696
references.citation: Annu Rev Pathol. 2013 Jan 24;8:277-302
references.pmid: 23092187